Androgenetic alopecia in women and men is not related to COVID-19 infection severity: a prospective cohort study of hospitalized COVID-19 patients.
作者信息
Torabi S, Mozdourian M, Rezazadeh R, Payandeh A, Badiee S, Darchini-Maragheh E
机构信息
Cutaneous Leishmaniasis Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Lung Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
出版信息
J Eur Acad Dermatol Venereol. 2021 Sep;35(9):e553-e556. doi: 10.1111/jdv.17353. Epub 2021 Jun 1.
Abstract
摘要
相似文献
1
Androgenetic alopecia in women and men is not related to COVID-19 infection severity: a prospective cohort study of hospitalized COVID-19 patients.男女雄激素性脱发与新冠病毒感染严重程度无关：一项对新冠病毒感染住院患者的前瞻性队列研究。
J Eur Acad Dermatol Venereol. 2021 Sep;35(9):e553-e556. doi: 10.1111/jdv.17353. Epub 2021 Jun 1.
2
Association of androgenetic alopecia and severity of coronavirus disease 2019.雄激素性脱发与 2019 冠状病毒病严重程度的相关性。
J Cosmet Dermatol. 2022 Mar;21(3):874-879. doi: 10.1111/jocd.14683. Epub 2021 Dec 17.
3
Androgenetic alopecia and COVID-19: Is there a clinical connection?雄激素性脱发与 COVID-19：二者存在临床关联吗？
J Cosmet Dermatol. 2022 Feb;21(2):420-425. doi: 10.1111/jocd.14670. Epub 2021 Dec 15.
4
Androgenetic alopecia and COVID-19: A review of the hypothetical role of androgens.雄激素性脱发与 COVID-19：雄激素的假设作用综述。
Dermatol Ther. 2021 Jul;34(4):e15004. doi: 10.1111/dth.15004. Epub 2021 Jun 9.
5
Comment on "Androgenetic alopecia present in the majority of patients hospitalized with COVID-19".关于“大多数因新冠肺炎住院的患者存在雄激素性脱发”的评论
J Am Acad Dermatol. 2021 Jan;84(1):e51-e52. doi: 10.1016/j.jaad.2020.08.087. Epub 2020 Aug 26.
6
Reply to: "Comment on 'Androgenetic alopecia present in the majority of patients hospitalized with COVID-19'".回复：“对‘大多数因 COVID-19 住院患者存在雄激素性脱发’的评论”
J Am Acad Dermatol. 2021 Jan;84(1):e53-e54. doi: 10.1016/j.jaad.2020.08.088. Epub 2020 Aug 26.
7
Androgenetic alopecia may be associated with weaker COVID-19 T-cell immune response: An insight into a potential COVID-19 vaccine booster.雄激素性脱发可能与新冠病毒T细胞免疫反应较弱有关：对潜在新冠病毒疫苗加强针的深入探讨。
Med Hypotheses. 2021 Jan;146:110439. doi: 10.1016/j.mehy.2020.110439. Epub 2020 Nov 28.
8
COVID-19 induced telogen effluvium.COVID-19 引发的休止期脱发。
Dermatol Ther. 2021 Nov;34(6):e15175. doi: 10.1111/dth.15175. Epub 2021 Nov 6.
9
Androgen sensitivity gateway to COVID-19 disease severity.雄激素敏感性是 COVID-19 疾病严重程度的关键。
Drug Dev Res. 2020 Nov;81(7):771-776. doi: 10.1002/ddr.21688. Epub 2020 May 15.
10
Alopecia and severity of COVID-19: a cross-sectional study in Peru.脱发与 COVID-19 严重程度：秘鲁的一项横断面研究。
Infez Med. 2021 Mar 1;29(1):37-45.
引用本文的文献
1
Male-pattern hair loss: Comprehensive identification of the associated genes as a basis for understanding pathophysiology.男性型脱发：相关基因的全面鉴定作为理解病理生理学的基础。
Med Genet. 2023 Apr 5;35(1):3-14. doi: 10.1515/medgen-2023-2003. eCollection 2023 Apr.
2
A Cross-Sectional Study on Post-Coronavirus Disease (COVID-19) Hair Loss at a Tertiary Care Hospital.某三级护理医院关于冠状病毒病（COVID-19）后脱发的横断面研究
Dermatol Pract Concept. 2023 Oct 1;13(4):e2023263. doi: 10.5826/dpc.1304a263.
3
Alopecia in patients with COVID-19: A systematic review and meta-analysis.新型冠状病毒肺炎患者的脱发：一项系统评价与荟萃分析
JAAD Int. 2022 Jun;7:67-77. doi: 10.1016/j.jdin.2022.02.006. Epub 2022 Feb 22.
4
Systematic investigation of a potential epidemiological and genetic association between male androgenetic alopecia and COVID-19.男性雄激素性脱发与新型冠状病毒肺炎之间潜在的流行病学和遗传学关联的系统研究。
Skin Health Dis. 2021 Dec;1(4):e72. doi: 10.1002/ski2.72. Epub 2021 Oct 21.
本文引用的文献
1
Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men.抗雄激素可能预防严重的新冠病毒疾病结局：一项对77名住院男性的前瞻性队列研究结果
J Eur Acad Dermatol Venereol. 2021 Jan;35(1):e13-e15. doi: 10.1111/jdv.16953. Epub 2020 Oct 21.
2
Androgen receptor genetic variant predicts COVID-19 disease severity: a prospective longitudinal study of hospitalized COVID-19 male patients.雄激素受体基因变异可预测新冠病毒疾病严重程度：一项针对住院新冠男性患者的前瞻性纵向研究。
J Eur Acad Dermatol Venereol. 2021 Jan;35(1):e15-e17. doi: 10.1111/jdv.16956. Epub 2020 Oct 21.
3
Male balding is a major risk factor for severe COVID-19.男性脱发是重症新冠病毒肺炎的一个主要风险因素。
J Am Acad Dermatol. 2020 Nov;83(5):e353-e354. doi: 10.1016/j.jaad.2020.07.062. Epub 2020 Jul 22.
4
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）进入细胞依赖于 ACE2 和 TMPRSS2，可被一种临床验证的蛋白酶抑制剂所阻断。
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
5
The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.雄激素调节的蛋白酶TMPRSS2激活了一个涉及肿瘤微环境成分的蛋白水解级联反应，并促进前列腺癌转移。
Cancer Discov. 2014 Nov;4(11):1310-25. doi: 10.1158/2159-8290.CD-13-1010. Epub 2014 Aug 13.
6
TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein.TMPRSS2 和 ADAM17 对 ACE2 的切割具有差异性，只有 TMPRSS2 的蛋白水解作用才能增强严重急性呼吸综合征冠状病毒刺突蛋白驱动的进入。
J Virol. 2014 Jan;88(2):1293-307. doi: 10.1128/JVI.02202-13. Epub 2013 Nov 13.
7
Androgenetic alopecia in men aged 40-69 years: prevalence and risk factors.40 - 69岁男性雄激素性脱发：患病率及危险因素
Br J Dermatol. 2003 Dec;149(6):1207-13. doi: 10.1111/j.1365-2133.2003.05565.x.
Zotero 插件